Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify

Earnings Call Insights: Lantern Pharma (LTRN) Q4 2025

MANAGEMENT VIEW

* Panna Sharma, President, CEO & Director, highlighted, "2025 was a defining year for Lantern Pharma. We achieved clinical validation, we believe, across multiple programs while establishing the foundation for our next phase of growth." Sharma stated that the company reached "encouraging and a unique development with LP-300 in the Phase II HARMONIC observations, combined with also a successful Phase Ia completion for our LP-184 clinical trial and most recently, an FDA IND clearance for our pediatric CNS cancer program through Starlight Therapeutics."
* Sharma addressed rumors regarding his departure: "This is categorically untrue and appears to be rooted in a deliberate and perhaps malicious attempt to manipulate our stock price."
* Sharma discussed the advancement of the HARMONIC trial for LP-300, noting the completion of targeted enrollment in Japan ahead of schedule and ongoing patient enrollment in the U.S., Japan, and Taiwan. He shared that the Phase II trial has shown an "86% clinical benefit rate and a 43% objective response rate in its initial safety lead-in cohort, including 1 patient with a durable complete response and survival continuing for nearly 2 years."
* Sharma announced a Type C meeting with the FDA scheduled for mid-May 2026, seeking feedback on protocol amendments for LP-300, focusing on patient enrollment with the EGFR exon 21 L858R mutation, increasing treatment cycles, and moving to a single-arm Simon 2-stage design.
* On LP-184, Sharma reported "a 48% clinical benefit rate at or above the therapeutic threshold" in a Phase I trial with 63 patients and emphasized mechanistic validation for DNA damage repair mutations.
* Starlight Therapeutics received FDA IND clearance for a Phase I pediatric CNS cancer trial, with STAR-001 gaining multiple rare pediatric disease and orphan drug designations, providing Lantern the potential to obtain FDA priority review vouchers.
* On the AI front, Sharma introduced the commercial launch of withZeta, a "multi-agentic system aimed at conquering rare cancers," and discussed the establishment of an AI center of excellence in India.
* CFO David Margrave stated, "Our general and administrative expenses were approximately $1.5 million for the fourth quarter of 2025 compared to approximately $1.6 million in the prior year period. R&D expenses were approximately $2.7 million for the fourth quarter of 2025 compared to approximately $4.3 million in the fourth quarter of 2024. We recorded a net loss of approximately $4.1 million for the fourth quarter of 2025 or $0.36 per share compared to a net loss of approximately $5.9 million or $0.54 per share for the fourth quarter of 2024."

OUTLOOK

* The company anticipates advancing clinical programs, expanding the RADR platform's commercial reach, and focusing on the withZeta platform launch at the AACR in the next month.
* Management indicated a need to raise "substantial additional funding in the near future," and current cash, cash equivalents, and marketable securities are expected to fund operations until "at least approximately late July 2026 to mid-September 2026."
* Sharma said, "We'll also be pursuing additional funding, including potential grant revenue to fund planned operations and clinical advancement of our precision oncology trials."

FINANCIAL RESULTS

* R&D expenses for the quarter were $2.7 million, general and administrative expenses were $1.5 million, and net loss for the quarter was ($4.1 million) or ($0.36) per share.
* For the full year, R&D expenses were $11.5 million, general and administrative expenses $6.5 million, and net loss was ($17.1 million) or ($1.57) per share.
* Cash, cash equivalents, and marketable securities stood at $10.1 million as of December 31, 2025.
* CFO Margrave said, "Our R&D expenses continue to exceed our G&A expenses by a strong margin, reflecting our focus on advancing our product candidates and pipeline."

Q&A

* NOT_APPLICABLE: The transcript did not contain a live analyst Q&A; participants were instructed to submit questions via email or an online tool, and no analyst exchange is included in the transcript.

SENTIMENT ANALYSIS

* There is no analyst input in the call transcript; therefore, direct sentiment from analysts cannot be assessed.
* Management maintained a confident tone in prepared remarks, using phrases such as "We believe that we had encouraging and a unique development" and "we're laser-focused on executing our dual engine strategy."
* Compared to the previous quarter, management’s tone remains positive and forward-looking, with continued emphasis on AI-driven innovation, clinical advancement, and commercial opportunities, but now also explicitly addressing public rumors about leadership stability.

QUARTER-OVER-QUARTER COMPARISON

* Guidance now includes a more urgent tone regarding the need for "substantial additional funding in the near future," compared to the previous quarter’s expectation of adequate cash into Q3 2026.
* Strategic focus has evolved, with greater emphasis on the commercial rollout of withZeta and expansion of the AI business model, compared to prior emphasis on clinical trial progress.
* Key financial metrics show a decrease in both R&D expenses and net loss compared to the previous quarter, reflecting further cost discipline.
* Management tone remains confident and future-focused, but the direct address of CEO departure rumors signals heightened sensitivity to investor sentiment.
* No analyst Q&A this quarter, in contrast to the previous quarter where analysts posed questions about trial milestones, Zeta development, and clinical program timelines.

RISKS AND CONCERNS

* Management explicitly warned of the need for substantial additional funding and a limited operational runway, with cash only expected to last until late July 2026 to mid-September 2026.
* CEO Sharma addressed the impact of “malicious and fake news” regarding management stability, noting harm to the company and investors, and announced plans to pursue legal action.
* The advancement of planned clinical trials and commercial initiatives is contingent on securing new funding.

FINAL TAKEAWAY

Lantern Pharma’s management emphasized that the company’s AI-driven clinical pipeline and the commercial launch of withZeta position it for future growth, with a combined market potential exceeding $15 billion and approaching $20 billion. Management underscored a disciplined reduction in operating expenses and highlighted key clinical and regulatory milestones, but also acknowledged the need to secure substantial new funding to sustain operations and progress clinical and commercial initiatives into 2026.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/ltrn/earnings/transcripts]

MORE ON LANTERN PHARMA

* Lantern Pharma Inc. 2025 Q4 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4887256-lantern-pharma-inc-2025-q4-results-earnings-call-presentation]
* Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript [https://seekingalpha.com/article/4887241-lantern-pharma-inc-ltrn-q4-2025-earnings-call-prepared-remarks-transcript]
* Lantern Pharma reports Q4 results [https://seekingalpha.com/news/4570391-lantern-pharma-reports-q4-results]
* Seeking Alpha’s Quant Rating on Lantern Pharma [https://seekingalpha.com/symbol/LTRN/ratings/quant-ratings]
* Historical earnings data for Lantern Pharma [https://seekingalpha.com/symbol/LTRN/earnings]